HTG Molecular Diagnostics, Inc. (HTGM) News
Filter HTGM News Items
HTGM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HTGM News Highlights
- HTGM's 30 day story count now stands at 2.
- Over the past 19 days, the trend for HTGM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, ARIZ and BIO are the most mentioned tickers in articles about HTGM.
Latest HTGM News From Around the Web
Below are the latest news stories about HTG MOLECULAR DIAGNOSTICS INC that investors may wish to consider to help them evaluate HTGM as an investment opportunity.
Why Is Coinbase (COIN) Stock Down 16% Today?Coinbase (COIN) stock is falling on Tuesday with heavy trading following news that the SEC is suing the crypto exchange. |
Why Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?HTG Molecular Diagnostics (HTGM) stock is falling on Tuesday after the company announced a Chapter 11 bankruptcy filing. |
Why Is Zura Bio (ZURA) Stock Up 9% Today?Zura Bio (ZURA) stock is on the rise Tuesday alongside a couple of positive pieces of news from the clinical-stage biotechnology company. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! |
Why Are HTG Molecular Diagnostics Shares Plunging TodayHTG Molecular Diagnostics (NASDAQ: HTGM) stock is down on Tuesday after the company announced a Chapter 11 bankruptcy filing. According to the filing, HTG Molecular Diagnostics will operate as a "debtor-in-possession" business during the bankruptcy. It's also seeking a variety of first-day motions that will allow it to continue normal operations. The filing also accelerates the obligations of the company's debts, including a $2.68 million loan held by Silicon Valley Bank, now a division of First |
HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International ConventionTUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platfor |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning! |
HTG Highlights the Advantages of Its Drug Discovery EngineTUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG’s objective is to develop best-in-class molecules for the treatment of |
HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business HighlightsTUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the |
HTG Provides Update on Drug Discovery Partnering InitiativeTUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG’s proprietary RN |